Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid cultures
Journal for ImmunoTherapy of Cancer · 2024-11 · 12 (11) · e009494
DOI: 10.1136/jitc-2024-009494 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 04.11.2024. Verfasst von Julijan Kabiljo und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Organoids, Coculture Techniques. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fellinger Cancer Research Foundation, Österreichische Forschungsförderungsgesellschaft, City of Vienna Fund for Innovative Interdisciplinary Cancer Research.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patient-derived colorectal cancer (CRC) organoids (PDOs) solely consisting of malignant cells led to major advances in the understanding of cancer treatments. Yet, a major limitation is the absence of cells from the tumor microenvironment, thereby prohibiting potential investigation of treatment responses on immune and structural cells. Currently there are sparse reports describing the interaction of PDOs, cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) in complex primary co-culture assay systems.
Methods
Primary PDOs and patient matched CAF cultures were generated from surgical resections. Co-culture systems of PDOs, CAFs and monocytic myeloid cells were set up to recapitulate features seen in patient tumors. Single-cell transcriptomics and flow cytometry was used to show effects of culture systems on TAM populations in the co-culture assays under chemotherapeutic and oncolytic viral treatment.
Results
In contrast to co-cultures of tumor cells and monocytes, CAF/monocyte co-cultures and CAF/monocyte/tumor cell triple cultures resulted in a partial differentiation into macrophages and a phenotypic switch, characterized by the expression of major immunosuppressive markers comparable to TAMs in CRC. Oxaliplatin and 5-fluorouracil, the standard-of-care chemotherapy for CRC, induced polarization of macrophages to a pro-inflammatory phenotype comparable to the immunogenic effects of treatment with an oncolytic virus. Monitoring phagocytosis as a functional proxy to macrophage activation and subsequent onset of an immune response, revealed that chemotherapy-induced cell death, but not virus-mediated cell death, is necessary to induce phagocytosis of CRC cells. Moreover, CAFs enhanced the phagocytic activity in chemotherapy treated CRC triple cultures.
Conclusions
Primary CAF-containing triple cultures successfully model TAM-like phenotypes ex vivo and allow the assessment of their functional and phenotypic changes in response to treatments following a precision medicine approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna, Vienna, Austria.
- Ludwig Boltzmann Institute Applied Diagnostics, Medical University of Vienna, Vienna, Austria.
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Center of Pathobiochemistry and Genetics, Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
- Department of Pathology, Medical University of Vienna, Vienna, Austria.
- Center for Cancer Research, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Julijan Kabiljo, Johannes Laengle, Dietmar Herndler Brandstetter, Gerda Egger, Michael Bergmann
Förderung
- Fellinger Cancer Research Foundation
- Österreichische Forschungsförderungsgesellschaft
- City of Vienna Fund for Innovative Interdisciplinary Cancer Research
- Österreichischen Akademie der Wissenschaften
- Vienna Science and Technology Fund
- Comprehensive Cancer Center
- Austrian Science Fund
Zitieren
APA
Kabiljo, J., Theophil, A., Homola, J., Renner, A. F., Stürzenbecher, N., Ammon, D., Zirnbauer, R., Stang, S., Tran, L., Laengle, J., Kulu, A., Chen, A., Fabits, M., Atanasova, V. S., Pusch, O., Weninger, W., Walczak, H., Herndler Brandstetter, D., Egger, G., …, & Bergmann, M. (2024). Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid cultures. Journal for ImmunoTherapy of Cancer, 12(11), e009494. https://doi.org/10.1136/jitc-2024-009494
Vancouver
Kabiljo J, Theophil A, Homola J, Renner AF, Stürzenbecher N, Ammon D, et al. Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid cultures. Journal for ImmunoTherapy of Cancer. 2024;12(11):e009494. doi:10.1136/jitc-2024-009494
BibTeX
@article{Kabiljo2024,
author = {Kabiljo, Julijan and Theophil, Anna and Homola, Jakob and Renner, Annalena F and Stürzenbecher, Nathalie and Ammon, Daphni and Zirnbauer, Rebecca and Stang, Simone and Tran, Loan and Laengle, Johannes and Kulu, Askin and Chen, Anna and Fabits, Markus and Atanasova, Velina S and Pusch, Oliver and Weninger, Wolfgang and Walczak, Henning and Herndler Brandstetter, Dietmar and Egger, Gerda and Dolznig, Helmut and Kusienicka, Anna and Farlik, Matthias and Bergmann, Michael},
title = {Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid cultures},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {11},
pages = {e009494},
doi = {10.1136/jitc-2024-009494}
}
EUVIMED